Atezolizumab Consolidation Impresses in High-Risk DLBCL

Published Date: 17 Jun 2024

Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation?

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Atezolizumab Consolidation Impresses in High-Risk DLBCL

2.

Breast cancer: Why it's difficult to treat and what new approaches are on the horizon

3.

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.

4.

Error on the MGUS-Autoimmune Disease Association.

5.

Veterans of the Navy have high lung cancer rates associated with asbestos use.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot